Published in Bioconjug Chem on November 19, 2006
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest Surg (2008) 2.41
Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm (2009) 1.42
Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev (2011) 1.36
Determination of optimal rhodamine fluorophore for in vivo optical imaging. Bioconjug Chem (2008) 1.18
Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore. Cancer Sci (2007) 1.09
Two-step synthesis of galactosylated human serum albumin as a targeted optical imaging agent for peritoneal carcinomatosis. J Med Chem (2010) 0.94
Comparison of the Photobleaching and Photostability Traits of Alexa Fluor 568- and Fluorescein Isothiocyanate- conjugated Antibody. Cell J (2011) 0.91
Fluorescence lifetime imaging of activatable target specific molecular probes. Contrast Media Mol Imaging (2010) 0.90
Platinum compounds for high-resolution in vivo cancer imaging. ChemMedChem (2014) 0.83
Activatable optical imaging with a silica-rhodamine based near infrared (SiR700) fluorophore: a comparison with cyanine based dyes. Bioconjug Chem (2011) 0.78
Bis-arylidene oxindole-betulinic Acid conjugate: a fluorescent cancer cell detector with potent anticancer activity. ACS Med Chem Lett (2015) 0.77
The relative brightness of PEG lipid-conjugated polymer nanoparticles as fluid-phase markers in live cells. Anal Bioanal Chem (2012) 0.75
Fluorescence-lifetime molecular imaging can detect invisible peritoneal ovarian tumors in bloody ascites. Cancer Sci (2014) 0.75
Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev (2016) 0.75
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 9.12
Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol (2002) 6.06
The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer (2005) 5.83
Fluorescence microscopy. Nat Methods (2005) 4.06
Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci U S A (2000) 3.24
Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol (2002) 1.83
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. Oncology (1990) 1.47
Fluorescent labeling of endoplasmic reticulum. Methods Cell Biol (1989) 1.24
Ligand/receptor internalization: a spectroscopic analysis and a comparison of ligand binding, cellular response, and internalization by human neutrophils. J Cell Biochem (1982) 1.11
Cell transduction pathways of transportans. Bioconjug Chem (2005) 1.06
Targeted optical imaging of cancer cells using lectin-binding BODIPY conjugated avidin. Biochem Biophys Res Commun (2006) 1.05
In vivo spectral fluorescence imaging of submillimeter peritoneal cancer implants using a lectin-targeted optical agent. Neoplasia (2006) 1.04
Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model. Bioconjug Chem (1998) 0.97
Individual acidic organelle pH measurements by capillary electrophoresis. Anal Chem (2006) 0.97
Imaging techniques for posterior uveitis. Curr Opin Ophthalmol (2004) 0.95
Fluorescein and indocyanine green angiography in vascular chorioretinal diseases. Semin Ophthalmol (1998) 0.94
Fluorescein angiography: techniques and toxicity. Int Ophthalmol Clin (1977) 0.81
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64
Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem (2002) 4.54
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) (2008) 4.08
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76
betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol (2008) 2.75
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol (2013) 2.62
Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol (2012) 2.59
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res (2009) 2.51
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging (2009) 2.21
MRI of tumor angiogenesis. J Magn Reson Imaging (2007) 2.19
Highly sensitive fluorescence probes for nitric oxide based on boron dipyrromethene chromophore-rational design of potentially useful bioimaging fluorescence probe. J Am Chem Soc (2004) 2.12
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol (2011) 2.10
In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res (2007) 2.01
Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer (2013) 1.97
Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol (2007) 1.92
Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol (2009) 1.89
Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int (2007) 1.86
Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett (2006) 1.80
Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res (2007) 1.76
Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol (2009) 1.76
Mechanistic background and clinical applications of indocyanine green fluorescence imaging of hepatocellular carcinoma. Ann Surg Oncol (2013) 1.76
Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res (2010) 1.74
Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74
Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano (2007) 1.70
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Radiologic manifestations of Proteus syndrome. Radiographics (2004) 1.66
In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia (2007) 1.65
Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res (2002) 1.64
A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate. Cancer Res (2007) 1.64
H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol (2009) 1.56
Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano (2012) 1.56
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst (2004) 1.55
In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther (2009) 1.55
Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem (2012) 1.55
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol (2006) 1.46
An enzymatically activated fluorescence probe for targeted tumor imaging. J Am Chem Soc (2007) 1.46
Imaging of the lymphatic system: new horizons. Contrast Media Mol Imaging (2006) 1.46